| Related Articles |
The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial.
J Psychiatry Neurosci. 2016 Oct;41(6):422-430
Authors: Tebartz van Elst L, Maier S, Klöppel S, Graf E, Killius C, Rump M, Sobanski E, Ebert D, Berger M, Warnke A, Matthies S, Perlov E, Philipsen A
Abstract
BACKGROUND: Based on animal research several authors have warned that the application of methylphenidate, the first-line drug for the treatment of attention-deficit/hyperactivity disorder (ADHD), might have neurotoxic effects potentially harming the brain. We investigated whether methylphenidate application, over a 1-year period, results in cerebral volume decrease.
METHODS: We acquired structural MRIs in a double-blind study comparing methylphenidate to placebo. Global and regional brain volumes were analyzed at baseline, after 3 months and after 12 months using diffeomorphic anatomic registration through exponentiated lie algebra.
RESULTS: We included 131 adult patients with ADHD into the baseline sample, 98 into the 3-month sample (54 in the methylphenidate cohort and 44 in the placebo cohort) and 76 into the 1-year sample (37 in the methylphenidate cohort and 29 in the placebo cohort). Methylphenidate intake compared with placebo did not lead to any detectable cerebral volume loss; there was a trend toward bilateral cerebellar grey matter increase.
LIMITATIONS: Detecting possible neurotoxic effects of methylphenidate might require a longer observation period.
CONCLUSION: There is no evidence of grey matter volume loss after 1 year of methylphenidate treatment in adult patients with ADHD.
PMID: 27575717 [PubMed – in process]
via https://www.ncbi.nlm.nih.gov/pubmed/27575717?dopt=Abstract
